ArticleNature communications2024

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.

Stephan Spahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.